{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:54:48Z","timestamp":1791863688121,"version":"4.3.4"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0226276","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T13:35:29Z","timestamp":1576071329000},"page":"e0226276","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate"],"prefix":"10.1371","volume":"14","author":[{"given":"Linn","family":"Hermansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4748-0446","authenticated-orcid":true,"given":"Staffan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"McCallister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariro","family":"Makadzange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-1020","authenticated-orcid":true,"given":"Magnus","family":"Gisslen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"issue":"1","key":"pone.0226276.ref001","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12068","article-title":"Monocyte\/macrophages and their role in HIV neuropathogenesis","volume":"254","author":"TH Burdo","year":"2013","journal-title":"Immunol Rev"},{"issue":"5","key":"pone.0226276.ref002","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/00365549409011810","article-title":"Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study","volume":"26","author":"M Gisslen","year":"1994","journal-title":"Scand J Infect Dis"},{"issue":"6831","key":"pone.0226276.ref003","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/35073667","article-title":"Pathways to neuronal injury and apoptosis in HIV-associated dementia","volume":"410","author":"M Kaul","year":"2001","journal-title":"Nature"},{"issue":"15","key":"pone.0226276.ref004","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1097\/QAD.0000000000001950","article-title":"Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment","volume":"32","author":"G Ulfhammer","year":"2018","journal-title":"AIDS"},{"key":"pone.0226276.ref005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1742-2094-10-62","article-title":"Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy","volume":"10","author":"A Yilmaz","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"1\u20132","key":"pone.0226276.ref006","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"A Petzold","year":"2005","journal-title":"J Neurol Sci"},{"key":"pone.0226276.ref007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4137\/JCNSD.S13821","article-title":"Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke","volume":"6","author":"C Hjalmarsson","year":"2014","journal-title":"J Cent Nerv Syst Dis"},{"issue":"22","key":"pone.0226276.ref008","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"CH Lu","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"pone.0226276.ref009","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/acn3.290","article-title":"Plasma neurofilament light chain predicts progression in progressive supranuclear palsy","volume":"3","author":"JC Rojas","year":"2016","journal-title":"Annals of clinical and translational neurology"},{"issue":"5","key":"pone.0226276.ref010","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"J Bergman","year":"2016","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"5","key":"pone.0226276.ref011","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ene.13274","article-title":"Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis","volume":"24","author":"I Hakansson","year":"2017","journal-title":"Eur J Neurol"},{"issue":"10","key":"pone.0226276.ref012","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"M Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"pone.0226276.ref013","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","article-title":"Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls","volume":"17","author":"A Yilmaz","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"pone.0226276.ref014","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s00415-006-0481-8","article-title":"CSF neurofilament protein (NfL)\u2014a marker of active HIV-related neurodegeneration","volume":"254","author":"S Abdulle","year":"2007","journal-title":"J Neurol"},{"issue":"2","key":"pone.0226276.ref015","doi-asserted-by":"crossref","first-page":"e88591","DOI":"10.1371\/journal.pone.0088591","article-title":"Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients","volume":"9","author":"J Jessen Krut","year":"2014","journal-title":"PLoS One"},{"issue":"15","key":"pone.0226276.ref016","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1212\/01.wnl.0000277635.05973.55","article-title":"Antiretroviral treatment reduces increased CSF neurofilament protein (NfL) in HIV-1 infection","volume":"69","author":"A Mellgren","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"pone.0226276.ref017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/infdis\/jix553","article-title":"Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers","volume":"217","author":"RA van Zoest","year":"2017","journal-title":"J Infect Dis"},{"key":"pone.0226276.ref018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","article-title":"Plasma Concentration of the Neurofilament Light Protein (NfL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study","volume":"3","author":"M Gisslen","year":"2016","journal-title":"EBioMedicine"},{"issue":"8","key":"pone.0226276.ref019","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"F Piehl","year":"2018","journal-title":"Mult Scler"},{"issue":"10","key":"pone.0226276.ref020","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"O Hansson","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"pone.0226276.ref021","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"LM Byrne","year":"2017","journal-title":"Lancet Neurol"},{"issue":"5","key":"pone.0226276.ref022","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease","volume":"74","author":"N Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"pone.0226276.ref023","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"PJ Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pone.0226276.ref024","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue","volume":"49","author":"WA Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0226276.ref025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"A Mills","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"issue":"4","key":"pone.0226276.ref026","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","article-title":"Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment","volume":"34","author":"E DeJesus","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"pone.0226276.ref027","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","article-title":"Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals","volume":"78","author":"R Begley","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"pone.0226276.ref028","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.30.8.924","article-title":"Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures","volume":"30","author":"J van Gelder","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"pone.0226276.ref029","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1128\/AAC.01089-12","article-title":"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro","volume":"56","author":"EI Lepist","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0226276.ref030","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bcp.2007.01.027","article-title":"Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein","volume":"73","author":"CH Storch","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"pone.0226276.ref031","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpba.2018.04.035","article-title":"Development and validation of an LC-MS\/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid","volume":"156","author":"AJ Ocque","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"pone.0226276.ref032","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/QAI.0b013e318247ec54","article-title":"Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir","volume":"59","author":"BM Best","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0226276.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-8454-3-1","article-title":"The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses","volume":"3","author":"C Anthonypillai","year":"2006","journal-title":"Cerebrospinal fluid research"},{"issue":"3","key":"pone.0226276.ref034","first-page":"1509","article-title":"Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid","volume":"282","author":"K Takasawa","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"pone.0226276.ref035","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3851\/IMP2767","article-title":"Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors","volume":"19","author":"RA Bam","year":"2014","journal-title":"Antivir Ther"},{"issue":"5","key":"pone.0226276.ref036","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/QAI.0b013e3181f5b3d1","article-title":"Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy","volume":"55","author":"A Yilmaz","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"pone.0226276.ref037","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/infdis\/jir667","article-title":"Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy","volume":"204","author":"V Dahl","year":"2011","journal-title":"J Infect Dis"},{"issue":"5","key":"pone.0226276.ref038","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s13365-012-0120-3","article-title":"Antiretroviral neurotoxicity","volume":"18","author":"K Robertson","year":"2012","journal-title":"J Neurovirol"},{"issue":"7","key":"pone.0226276.ref039","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1681\/ASN.2005010005","article-title":"Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study","volume":"16","author":"M Kurella","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"4\u20135","key":"pone.0226276.ref040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000430922","article-title":"Renal function and long-term decline in cognitive function: the Baltimore Longitudinal Study of Aging","volume":"41","author":"SL Seliger","year":"2015","journal-title":"Am J Nephrol"},{"issue":"6","key":"pone.0226276.ref041","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13365-018-0664-y","article-title":"Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy","volume":"24","author":"AM Anderson","year":"2018","journal-title":"J Neurovirol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T13:35:52Z","timestamp":1576071352000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226276"}},"subtitle":[],"editor":[{"given":"Alan","family":"Winston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,11]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0226276","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,11]]}}}